Health Care Ticks Down Amid Deal Activity - Health Care Roundup

Dow Jones06-09 05:00

Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.

Incyte agreed to buy closely held biotech rival Vega Therapeutics for up to $2 billion, in a deal that would see Incyte acquiring drugs for bleeding disorders.

Johnson & Johnson agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that boosts the health-care conglomerate's oncology-drug pipeline.

Eli Lilly shares rose after a late-stage trial showed its drug was effective in weight loss and in alleviating obesity-linked conditions. Danish rival Novo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. Despite the blockbuster sales data, shares of Novo fell sharply, reflecting investors' lofty expectations for GLP-1 drugs. Separately, analysts at brokerage Morgan Stanley warned that Novo Nordisk could soon face stiff generic competition for its Ozempic drug in several key global markets.

Swiss drug maker Roche Holding struck a deal with Nurix Therapeutics to license an experimental blood-cancer drug for up to $2.3 billion.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

June 08, 2026 17:00 ET (21:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642434179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642434179","market":"us","top_or_hot":-1,"title":"Health Care Ticks Down Amid Deal Activity - Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs. \n</p>\n<p>\n  Incyte agreed to buy closely held biotech rival Vega <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $2 billion, in a deal that would see Incyte acquiring drugs for bleeding disorders. \n</p>\n<p>\n  Johnson &amp; Johnson agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that boosts the health-care conglomerate's oncology-drug pipeline. \n</p>\n<p>\n  Eli Lilly shares rose after a late-stage trial showed its drug was effective in weight loss and in alleviating obesity-linked conditions. Danish rival <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. Despite the blockbuster sales data, shares of Novo fell sharply, reflecting investors' lofty expectations for GLP-1 drugs. Separately, analysts at brokerage Morgan Stanley warned that Novo Nordisk could soon face stiff generic competition for its Ozempic drug in several key global markets. \n</p>\n<p>\n  Swiss drug maker Roche Holding struck a deal with <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> to license an experimental blood-cancer drug for up to $2.3 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 17:00 ET (21:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Ticks Down Amid Deal Activity - Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Ticks Down Amid Deal Activity - Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 05:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs. \n</p>\n<p>\n  Incyte agreed to buy closely held biotech rival Vega <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $2 billion, in a deal that would see Incyte acquiring drugs for bleeding disorders. \n</p>\n<p>\n  Johnson &amp; Johnson agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that boosts the health-care conglomerate's oncology-drug pipeline. \n</p>\n<p>\n  Eli Lilly shares rose after a late-stage trial showed its drug was effective in weight loss and in alleviating obesity-linked conditions. Danish rival <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. Despite the blockbuster sales data, shares of Novo fell sharply, reflecting investors' lofty expectations for GLP-1 drugs. Separately, analysts at brokerage Morgan Stanley warned that Novo Nordisk could soon face stiff generic competition for its Ozempic drug in several key global markets. \n</p>\n<p>\n  Swiss drug maker Roche Holding struck a deal with <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> to license an experimental blood-cancer drug for up to $2.3 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 08, 2026 17:00 ET (21:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1732799900.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642434179","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642434179","pubTimestamp":1780952400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.Incyte agreed to buy closely held biotech rival Vega Therapeutics for up to $2 billion, in a deal that would see Incyte acquiring drugs for bleeding disorders.Johnson & Johnson agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that boosts the health-care conglomerate's oncology-drug pipeline.Eli Lilly shares rose after a late-stage trial showed its drug was effective in weight loss and in alleviating obesity-linked conditions. Danish rival Novo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. Despite the blockbuster sales data, shares of Novo fell sharply, reflecting investors' lofty expectations for GLP-1 drugs. Separately, analysts at brokerage Morgan Stanley warned that Novo Nordisk could soon face stiff generic competition for its Ozempic drug in several key glo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0210528500.USD":"JPM AMERICA EQUITY \"A\" ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","BK4127":"投资银行业与经纪业","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0106831901.USD":"贝莱德世界金融基金A2","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4516":"特朗普概念","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","XBI":"SPDR S&P Biotech ETF","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LABU":"三倍做多标普生物-Direxion","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","XLV":"健康照护类股ETF-SPDR","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV"},"translate_title":"医疗保健在交易活动中下跌-医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LABU":0.6,"XLV":1.5},"content_text":"Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs. \n\n\n  Incyte agreed to buy closely held biotech rival Vega Therapeutics for up to $2 billion, in a deal that would see Incyte acquiring drugs for bleeding disorders. \n\n\n  Johnson & Johnson agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that boosts the health-care conglomerate's oncology-drug pipeline. \n\n\n  Eli Lilly shares rose after a late-stage trial showed its drug was effective in weight loss and in alleviating obesity-linked conditions. Danish rival Novo Nordisk said prescriptions for its Wegovy weight-loss pill have surpassed three million since launching in early January. Despite the blockbuster sales data, shares of Novo fell sharply, reflecting investors' lofty expectations for GLP-1 drugs. Separately, analysts at brokerage Morgan Stanley warned that Novo Nordisk could soon face stiff generic competition for its Ozempic drug in several key global markets. \n\n\n  Swiss drug maker Roche Holding struck a deal with Nurix Therapeutics to license an experimental blood-cancer drug for up to $2.3 billion. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 17:00 ET (21:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642434179","isCrawlerRequest":true}